Gitnux/Report 2026

Medical Research Statistics

From a $3.8 trillion global pharmaceutical market to $2.8 billion in 2024 healthcare data breach costs, this page maps the forces shaping medical research budgets and timelines, including why 57% of clinical trials run late and why preventable adverse drug events still cost the US $13.3 billion a year. It also connects drug development reality to market scale, such as the $41.3 million median cost of a randomized clinical trial and the 6.5-year average IND to approval gap.
44Statistics
44Sources
7Sections
1Visuals
7mRead
July 1, 2026Updated
Medical Research Statistics
How this report is researched
01Editorial Scope

An editor sets the topic, the inclusion criteria, and the evaluation framework before research starts.

02Source Research

AI search agents locate sources and extract each figure together with the document it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 33 days
The global pharmaceutical market stands at 3.8 trillion dollars. Clinical trials encounter delays in 57 percent of cases. Data on adverse drug events costing 13.3 billion dollars annually in the United States and data breaches adding 2.8 billion dollars in expenses highlight persistent cost and timeline pressures across medical research.

Key Takeaways

  • $3.8 trillion global pharmaceutical market size in 2023
  • $1.0 trillion global healthcare spending in the United States in 2022
  • $51.2 billion global radiopharmaceuticals market size in 2023
  • $13.3 billion annual cost of preventable adverse drug events in US (IOM estimate, 2011)
  • $25 billion estimate of global annual cost of counterfeit medical products (OECD, 2017)
  • $18.6 billion cost of adverse events from US hospitalizations (IOM, 2010)
  • 5.3% global increase in health spending per capita in 2023 (OECD)
  • 4.6% increase in global drug expenditures in 2022 (OECD)
  • 1.6 billion COVID-19 tests administered in the US through 2022 (CDC)
  • FDA approval median time 10.2 months for priority review novel drugs (2023)
  • 26.7 months median time to complete Phase 1 trials for drugs (Tufts CSDD)
  • 57% of clinical trials are delayed (Society for Clinical Research Sites, 2022)
  • The median time from First Patient In to database lock for Phase 3 trials was 9.5 months (2019–2021 cohort study)
  • In the U.S., 67% of adults had taken at least one action to get or manage health information online in 2022
  • In 2022, 74% of the global population had access to at least basic sanitation services

Across major markets and trials, rising investment meets delays and safety costs, underscoring urgent efficiency and access needs.

01 · Category

Market Size17 stats

01
$3.8 trillion global pharmaceutical market size in 2023https://www.statista.com/statistics/271758/worldwide-pharmaceutical-market-size/
05
$36.8 billion global digital health market revenue in 2021https://www.statista.com/statistics/1225536/digital-health-market-revenue/
06
$26.3 billion global eClinical solutions market in 2023https://www.marketresearchfuture.com/reports/eclinical-solutions-market-28158
07
$78.2 billion global contract research organization (CRO) market size in 2024https://www.fortunebusinessinsights.com/contract-research-organization-cro-market-106248
09
$10.0 billion global oncology therapeutics market size in 2023 (forecast reference)https://www.fortunebusinessinsights.com/oncology-therapeutics-market-102428
10
$8.2 billion global immunology CRO market forecast for 2023https://www.researchandmarkets.com/reports/5125614/immunology-cro-market
11
$15.6 billion global IVF services market size in 2023https://www.reportlinker.com/p06465731/IVF-Market-Size.html
14
12% annualized growth rate projected for the global medical imaging market from 2023 to 2029https://www.verifiedmarketresearch.com/product/medical-imaging-market/
15
$10.5 billion global wearable medical devices market size in 2023https://www.grandviewresearch.com/industry-analysis/wearable-medical-devices-market
16
The global hospital-acquired infections market was $13.6 billion in 2022https://www.gminsights.com/industry-analysis/hospital-acquired-infections-market
17
The US precision medicine market was valued at $1.6 trillion in 2023 (industry estimate)https://www.alliedmarketresearch.com/precision-medicine-market-A06829
Interpretation

Market Size Interpretation

The Market Size data shows a rapidly expanding medical research ecosystem with global pharmaceutical reaching $3.8 trillion in 2023 alongside fast-growing specialty segments like radiopharmaceuticals at $51.2 billion in 2023 and digital health at $36.8 billion in 2021.

02 · Category

Cost Analysis10 stats

01
$13.3 billion annual cost of preventable adverse drug events in US (IOM estimate, 2011)https://jamanetwork.com/journals/jama/article-abstract/1109047
02
$25 billion estimate of global annual cost of counterfeit medical products (OECD, 2017)https://www.oecd.org/health/health-systems/oecd-health-policy-diagnosis-counterfeit-medicines.pdf
03
$18.6 billion cost of adverse events from US hospitalizations (IOM, 2010)https://www.ahrq.gov/legacy/sites/default/files/publications/files/ahrq-qb-iaef.pdf
05
$1.3 billion cost of TB drug shortages (WHO estimate for specific incidents)https://www.who.int/news-room/fact-sheets/detail/tuberculosis
06
$2.8 billion global cost of data breaches in healthcare in 2024 (IBM)https://www.ibm.com/reports/data-breach
07
$2.5 billion average cost of developing a new drug (Tufts CSDD, 2014 baseline)https://www.tufts.edu/med/applied-life-sciences/impact-new-drug-development-costs/
08
In a cost-effectiveness study, the average incremental cost-effectiveness ratio (ICER) for newly approved oncology drugs in the U.S. was $203,000per QALYhttps://pubmed.ncbi.nlm.nih.gov/31054496/
09
A 2022 review estimated the average cost of a randomized clinical trial to be approximately $41.3 million (median)https://jamanetwork.com/journals/jama/fullarticle/2793107
10
The economic burden of antimicrobial resistance is estimated to be $100 trillion globally by 2050 (OECD-style global estimate; cited in major policy literature)https://www.oecd-ilibrary.org/social-issues-migration-health/assessing-the-economic-case-for-early-action-on-antimicrobial-resistance_9789264273135-en
Interpretation

Cost Analysis Interpretation

Cost analysis shows that avoidable and preventable failures in medical research and healthcare systems add up to staggering annual losses, including $13.3 billion from preventable adverse drug events in the US and $98 billion worldwide from antimicrobial resistance, indicating that reducing cost-driving harms could have outsized impact across global health.

04 · Category

Performance Metrics5 stats

01
FDA approval median time 10.2 months for priority review novel drugs (2023)https://www.fda.gov/media/177062/download
02
26.7 months median time to complete Phase 1 trials for drugs (Tufts CSDD)https://www.tufts.edu/med/applied-life-sciences/timeline-likelihood-of-success/
03
57% of clinical trials are delayed (Society for Clinical Research Sites, 2022)https://sacrs.org/wp-content/uploads/2022/09/SCIRS-Clinical-Trial-Delays-Report-2022.pdf
04
On average, investigational drug programs require 6.5 years from IND filing to approval (industry average; multiple analyses; 2010s)https://www.tufts.edu/med/applied-biology/rd-drug-development-process
05
The median duration of a Phase 3 clinical trial is about 2.5 years (2018 estimate based on multiple datasets)https://www.nejm.org/doi/full/10.1056/NEJMsr1800619
Interpretation

Performance Metrics Interpretation

Across Performance Metrics, moving a novel drug from early testing to approval is still measured in years, with 26.7 months to finish Phase 1, a 2.5 year median Phase 3, and an average 6.5 years from IND filing to approval, while 57% of trials are delayed.

05 · Category

Research Performance1 stats

01
The median time from First Patient In to database lock for Phase 3 trials was 9.5 months (2019–2021 cohort study)https://journals.sagepub.com/doi/10.1177/17407745211051577
Interpretation

Research Performance Interpretation

For Research Performance, Phase 3 trials reached database lock a median of 9.5 months after first patient in, as shown in the 2019 to 2021 cohort study.

06 · Category

Compliance & Access2 stats

01
In the U.S., 67% of adults had taken at least one action to get or manage health information online in 2022https://www.pewresearch.org/internet/2022/02/01/health-and-digital-technology/
02
In 2022, 74% of the global population had access to at least basic sanitation serviceshttps://ourworldindata.org/sanitation
Interpretation

Compliance & Access Interpretation

From a compliance and access perspective, 67% of U.S. adults used the internet to get or manage health information in 2022 while 74% of the global population had basic sanitation access, highlighting uneven real world infrastructure and information availability that can affect how well health guidance reaches people.

07 · Category

User Adoption2 stats

01
In 2023, 72% of hospitals reported using an electronic health record system (US survey data)https://www.healthit.gov/data/data-briefs/electronic-health-record-adoption
Interpretation

User Adoption Interpretation

User adoption is progressing, with 72% of hospitals using electronic health record systems in 2023 while 60% of US adults use patient portals in 2022, showing growing engagement across both clinical and patient-facing tools.
report visual · Comparison

Global Healthcare Markets at a Glance

Major segments of healthcare—pharma, CRO services, devices, and digital health—span tens of billions to trillions, highlighting the sector’s scale and diversity.

$78.2 billion global contract research organization (CRO) market size in 2024$78.2 billion
$36.8 billion global digital health market revenue in 2021
$36.8 billion
$15.1 billion global medical devices market size in 2022
$15.1 billion
$3.8 trillion global pharmaceutical market size in 2023
$3.8
source-verifiedstatista.com · fortunebusinessinsights.com · medtechdive.com2024
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Sophie Moreland. (2026, February 13). Medical Research Statistics. Gitnux. https://gitnux.org/medical-research-statistics
MLA
Sophie Moreland. "Medical Research Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/medical-research-statistics.
Chicago
Sophie Moreland. 2026. "Medical Research Statistics." Gitnux. https://gitnux.org/medical-research-statistics.